DLinDMA |
|
Vaxjo ID |
241 |
|
Vaccine Adjuvant Name |
DLinDMA |
|
Alternative Names |
2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane |
|
Adjuvant VO ID |
VO_0005728
|
|
Description |
A cationic lipid used to form liposomes that deliver plasmid DNA into cells. Studied as a non-viral gene delivery vector for Lafora disease gene therapy |
|
Stage of Development |
Research |
|
Components |
DLinDMA and DOTAP were formulated characterized encoding laforin expression functional protein in HEK293 neuroblastoma cells |
|
Structure |
Used in liposomes with DOPE, DOPC, and cholesterol; forms cationic vesicles that bind DNA via electrostatic interaction |
|
Appearance |
Forms nanoparticles (~141 nm) in aqueous suspension with +33.5 mV zeta potential |
|
Storage |
Stored in aqueous suspension at room temperature post-sonication. |
|
Preparation |
Prepared by ethanol injection followed by probe sonication to produce liposomes. DNA is added at various mass ratios to form lipoplexes |
|
Dosage |
Commonly used at 32 µM for fluorescence imaging and 16 µM for immunoprecipitation (mass ratio DNA:liposome = 1:20) |
|
Function |
A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes |
|
Safety |
Low toxicity at working concentrations; minimal hemolysis in mice RBCs; better safety than commercial transfection reagents (PEI Max, Transit LT1) |
| References |
Vemana et al., 2021: Vemana HP, Saraswat A, Bhutkar S, Patel K, Dukhande VV. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (London, England). 2021; 16(13); 1081-1095. [PubMed: 33960213].
|
